Formycon AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 238
- Market Cap
- $1B
- Website
- http://formycon.com
Ocular Safety and Usability Study for FYB201 PFS
Phase 4
Completed
- Conditions
- Age-Related Macular DegenerationBranch Retinal Vein Occlusion with Macular EdemaCentral Retinal Vein Occlusion with Macular Edema
- Interventions
- Drug: FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Formycon AG
- Target Recruit Count
- 31
- Registration Number
- NCT06708624
- Locations
- 🇺🇸
Research Site, Eugene, Oregon, United States
Ocular Safety and Usability Study for FYB203 PFS
Phase 4
Completed
- Conditions
- Age-Related Macular DegenerationBranch Retinal Vein Occlusion with Macular EdemaCentral Retinal Vein Occlusion with Macular EdemaDiabetic Macular EdemaDiabetic Retinopathy
- Interventions
- Drug: FYB203 2 mg (0.05 mL of 40 mg/mL)
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Formycon AG
- Target Recruit Count
- 30
- Registration Number
- NCT06708637
- Locations
- 🇺🇸
Research Site, Eugene, Oregon, United States
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda As Add-on to Chemotherapy in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
Recruiting
- Conditions
- Non Small Cell Lung CancerNon-Squamous Non-Small Cell Lung Cancer
- Interventions
- Biological: FYB206Biological: Keytruda
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Formycon AG
- Target Recruit Count
- 524
- Registration Number
- NCT06643117
- Locations
- 🇲🇾
Formycon Investigative Site, Kuching, Malaysia
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
Phase 1
Recruiting
- Conditions
- Melanoma Stage IIIMelanoma, Stage II
- Interventions
- Biological: FYB206Biological: Keytruda
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Formycon AG
- Target Recruit Count
- 94
- Registration Number
- NCT06551064
- Locations
- 🇺🇦
Formycon Investigative Site, Kyiv, Ukraine
© Copyright 2025. All Rights Reserved by MedPath